Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

Safety & Toxicity Forecasting Services

Online Inquiry

Background Service What We Can Offer Workflow HighlightsFAQs Contact

Engineered cell therapies face formidable safety hurdles, including unpredictable cytokine storms, on-target/off-tumor toxicities, and complex neurotoxicity, which contribute to high clinical attrition. Creative Biolabs' Safety & Toxicity Forecasting Services are designed to systematically de-risk your pipeline by providing predictive, human-relevant safety assessments. We employ an integrated platform combining advanced organ-on-chip models, primary human tissue arrays, and longitudinal multi-omics biomarker profiling. This approach delivers high-fidelity, IND-ready toxicity data, enabling you to optimize candidate selection, refine therapeutic windows, and accelerate your development timeline with greater confidence.

Introduction

Despite its revolutionary success in hematologic malignancies, chimeric antigen receptor T-cell (CAR-T) therapy confronts profound translational hurdles in solid tumors, with lung cancer representing a formidable challenge. Beyond the barriers of antigen heterogeneity, an immunosuppressive microenvironment, and inefficient tumor trafficking, the therapy is significantly constrained by serious, potentially life-threatening toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and on-target/off-tumor effects. Accurately forecasting and mitigating these organ-specific toxicities is therefore not merely a safety consideration but a critical prerequisite for therapeutic efficacy and clinical translation.

Fig.1 Toxicity barriers in CAR-T immunotherapy. (OA Literature) Fig.1 Challenges of toxicity in CAR-T cell therapeutics.¹

Safety & Toxicity Forecasting Services at Creative Biolabs

Creative Biolabs provides the specialized infrastructure required to transform potential safety liabilities into manageable clinical strategies. We deliver high-resolution data packages that quantify cytokine storm potential, predict blood-brain barrier (BBB) integrity, and map organ-specific liabilities before your candidate reaches a single patient. By integrating these insights early, we help you optimize CAR constructs in your regulatory submissions.

Service Packages

Our suite of specialized services leverages cutting-edge human-relevant models and biomarker strategies to predict and de-risk critical safety challenges in engineered cell therapy development.

Preclinical Trial-on-Chip-based Cytokine Release Syndrome (CRS) Assessment Service

This service utilizes advanced microfluidic human immune system-on-chip platforms to model and predict the systemic inflammatory cascade of CRS. It enables the quantitative evaluation of cytokine storm kinetics, endothelial cell activation, and tissue-level damage in a physiologically relevant environment. Clients can rank CAR-T candidates, optimize dosing, and preclinically test rescue strategies to mitigate severe CRS risk before clinical trials.

Learn More →

CAR-T On-Target Off-Tumor Toxicity Assessment Service

We provide a comprehensive risk assessment of unintended CAR-T cell activity against healthy tissues expressing low target antigen levels. Using high-fidelity models like patient-derived organoids, we profile cytotoxicity across a panel of critical normal human cell types. This informs target selection, affinity tuning, and the development of logic-gated CARs to significantly enhance therapeutic safety.

Learn More →

CAR-T Neurotoxicity (ICANS) Assessment Service for Blood-Brain Barrier (BBB) Chip Model

This service employs a dynamic human BBB Chip model to predict the mechanisms of neurotoxicity (ICANS). By modeling the neurovascular unit under flow, we assess how CAR-T-derived cytokines compromise barrier integrity and activate glial cells. This provides crucial data for candidate selection and developing neuroprotective strategies to reduce ICANS incidence and severity.

Learn More →

Organ-Specific Toxicity Assessment Service for Engineered CAR-T

We deliver a holistic, organ-specific safety profile by integrating targeted in vitro organ-mimetic assays with longitudinal in vivo biomarker monitoring. This systematic approach identifies both direct and cytokine-mediated toxicities across vital organs, generating a comprehensive risk assessment. The output supports the design of safer clinical protocols and robust safety mitigation plans for regulatory submissions.

Learn More →

Our Service Process

Required Starting Materials:

Therapeutic Candidate: Purified CAR-T cell products, viral vectors, or scFv sequences in specified concentrations.
Mechanism of Action Summary: Documentation on target antigens and expected signaling pathways.
Experimental Objectives: Specific toxicity concerns such as suspected cross-reactivity with pulmonary or cardiac tissues.

Key Steps:

Workflow of safety & toxicity forecasting services at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Comprehensive Safety Profiles: Quantitative reports on cytokine release kinetics and IC50/EC50 values for inflammatory markers.
Imaging & Histopathology: High-resolution digital images of tissue cross-reactivity and organ-specific damage scores.
Strategic Recommendations: Expert guidance on product redesign or clinical monitoring plans based on predicted toxicities.

Key Advantages

Comprehensive Toxicity Profiling Platform: We offer an integrated evaluation pathway, progressing from preliminary in vitro assays through advanced organ-mimetic pilot studies to scaled validation batches.
Bespoke Model Optimization: Our service includes customizing assay parameters, such as refining reporter gene constructs and microenvironmental conditions, to ensure sensitive and specific toxicity readouts in your chosen tissue systems.
Large-Scale Multiplexed Analysis: We provide the capacity for high-throughput, multi-parameter analysis, enabling the simultaneous quantification of vast signaling networks and cytokine profiles across extensive donor cohorts.

FAQs

Q1: How do your On-Chip models compare to traditional animal testing?

A1: While animal models offer systemic observations, they frequently lack human-specific immune responses and tissue interactions. Our microphysiological systems utilize patient-relevant human cells to replicate organ-level functions and inflammatory cascades, enabling more clinically predictive assessments of complications such as CRS and neurotoxicity, thus reducing translational gaps early in development.

Q2: Can these services help optimize my CAR construct design?

A2: Absolutely. Our platform enables systematic comparison of CAR design elements, including co-stimulatory domains, hinge regions, and antigen-binding affinity, within physiologically relevant human tissue models. This allows for iterative refinement of your construct based on quantitative safety metrics, such as cytokine release and on-target/off-tumor activity, to prioritize designs with an optimized efficacy-to-toxicity profile.

Why Choose Us?

Creative Biolabs integrates cutting-edge cellular engineering with predictive safety science. By leveraging human-relevant organ-on-chip platforms and primary cell systems, we deliver translational insights beyond the limitations of conventional animal testing. Our specialized analysis accurately differentiates between acceptable on-target effects and critical off-tumor toxicities, enabling smarter therapeutic development.

How to Contact Us?

Our integrated forecasting platform translates CAR-T toxicity risks into actionable, data-driven strategies. Connect with our experts for a tailored consultation and proposal designed to accelerate your therapy's path to clinic with confidence.

Reference

Kandra, Prameela et al. "Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer." Frontiers in immunology vol. 13 903562. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2022.903562.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.